Curaleaf Likely to Face Wrongful Death Lawsuit Tied to Mislabeling CBD Products

Curaleaf可能面临与CBD产品标签错误有关的不当死亡诉讼

2021-12-21 04:55:00 Business Times

本文共4246个字,阅读需11分钟

Curaleaf Holdings, a vertically integrated multistate cannabis [and CBD] operator, is likely to face a wrongful death lawsuit, the latest in a string of lawsuits related to mislabeled products. Curaleaf is currently facing 10 lawsuits from consumers who allegedly ingested an incorrectly labeled CBD tincture that contained "undisclosed levels of THC," according to a product recall notice issued by the Oregon Liquor and Cannabis Commission (OLCC). The recall was issued Sept. 21 for a single batch of the mislabeled CBD product, which was produced by Cura CS LLC and sold under Curaleaf's Select brand. Curaleaf acquired Cura and its Select brand in 2019 in a $948.8-million all-stock deal. Peter Clateman, Curaleaf chief legal officer, tells Cannabis Business Times and Hemp Grower that about 500 bottles from the batch were sold. The OLCC expanded the recall Sept. 24 to include another Select tincture that said it contained 1,000 mg of THC on the label, but after a round of preliminary tests, the OLCC found that the product did not contain any detectable THC. According to OLCC, Curaleaf sold an estimated 630 units of the mislabeled tincture. Curaleaf acknowledged the mislabeling of the two tinctures was caused by "human error." "So, the most basic thing that happened is that there was an employee who mixed two sets of ingredients and put the THC-containing ingredients into the CBD product. It was error, and it was [a] clear error just because the products were labeled and the employee got confused. Instead of escalating or seeking to resolve the confusion, [he] just went ahead and filled the product," Clateman said. "We've done a root cause analysis, and that's where we got to. The employee's been reassigned out of production work." The mislabeled products have now led to multiple individuals filing lawsuits against the company, most of whom are being represented by Michael Fuller, a partner at the Underdog Law Office in Portland, Ore. Fuller said “dozens of people” contacted the firm expressing similar concerns related to the mislabeled products. "Most of them reached out to me through referral by reporters,” Fuller said. “An Idaho man was the first to contact the [law firm] about his experience after he was hospitalized." Fuller said the reporter who referred the plaintiff to the law firm recognized the firm from a previous class-action lawsuit Fuller filed against Cura for mislabeling cannabis products last year. The mislabeled products failed to state they contained non-cannabis-derived botanical terpenes, a mistake that Cura said was unintentional and due to “poor communication between its manufacturing and labeling and packaging personnel,” as reported by Portland Business Journal. (Cura also faced a $110,000 fine from OLCC for that mislabeling mishap, PBJ reported.)  "We negotiated a half-a-million-dollar settlement of that claim," Fuller said. "This shouldn't happen just because this is a relatively new industry. There's just simply no excuse for it, and they're setting the [legalization] movement back," Fuller said. "It's not accidents. It's cutting corners." Lawsuit Breakdown In the recent lawsuits, Fuller said all his clients–who range from males and females in their 30s to individuals in their late 70s–claimed they were experiencing "stroke-like" symptoms after allegedly consuming the mislabeled CBD product. Fuller said some of the alleged symptoms include slurred speech, loss of time, inability to stand, hallucination, psychosis, panic, pounding, heart rate, and thoughts that they were going to die. He said about half a dozen of his clients went to the emergency room following consumption–one of whom was allegedly life-flighted on two separate occasions after consumption, and another who allegedly had "unnecessary surgery" due to a misdiagnosed stroke. He added that many of his clients claimed they consumed the product multiple times without realizing it contained THC. The wrongful death lawsuit alleges the plaintiff who was life-flighted twice reportedly died from COVID-19 a few weeks after his second trip to the hospital following consumption; however, his family believes the "THC dosing was a substantial factor in his inability to survive COVID," Fuller said. "His family believes that it wasn't the THC that killed him, but his family believes that it was a substantial factor in affecting his health to where he was basically, after that experience, … convinced he was going to die; they say he was never the same," Fuller said, adding that the experience allegedly “weakened him.” His case is currently pending probate, Fuller said, and a wrongful death suit will be filed once the court approves the paperwork. “We're just waiting on the judge's signature,” Fuller said. “It's a very small county in Oregon called Lake County. And so, we don't have a lot of control over how quick things get processed there, but we've already drafted the lawsuit, and we just need the judgment from the Lake County judge appointing the personal representative because it's an estate claim and then the complaint will be filed." Fuller said all the claims are pretty "straightforward" product liability cases, as he believes Curaleaf is not denying that it "violated the law by putting THC in bottles that were advertised to only have CBD in them." On Dec. 16, Curaleaf's communications department offered the following response to Cannabis Business Times/Hemp Grower via email: Curaleaf Statement re: THC/CBD product labeling error While we cannot comment on any pending litigation, we can offer this response: A team member confused two containers during the filling and packaging process, one containing CBD and one containing THC. This resulted in a single batch of [CBD] tincture being labeled as THC [drops] and vice versa. The amount of THC was within the regulatory limit for a normal batch for our THC drops, but we understand that some customers may have consumed multiple doses. We have worked with the OLCC to recall the two batches in question, and the limited number of remaining units have been removed from sale. In response to this event, as initial steps, [we] have adjusted production practices and implemented new controls to improve quality assurance processes to further minimize the possibility of human error, enhancing camera visibility in product control areas and conducting additional training sessions with our production team. We will also be adding a secondary review of transfer of product between departments, batch records, and other documents.  We have also added a new Quality Technician position to [our Oregon facility], and have removed the individual responsible for the error during the filling and packaging process. We will continue to work closely with our local operations team to ensure safety and compliance best practices are followed in every step of production. Next Steps Some of the cases have already been settled. "Our approach has been to deal amicably and try to reach a settlement with people who have experienced negative effects from the product," Clateman said. The active cases will move forward separately, and Fuller said he expects some of them to be settled and others to go to trial by middle to late next year.   WASHINGTON, Dec. 15, 2021 – PRESS RELEASE – The Marijuana Policy Project announced that Toi Hutchinson will join the organization as its new president and CEO. Hutchinson, a former Illinois state senator, most recently served as senior adviser to Illinois Gov. J.B. Pritzker on cannabis legalization implementation.  For the past year, MPP Executive Director Steven Hawkins has led both MPP and the United States Cannabis Council (USCC). Hawkins will now exclusively focus his efforts on federal cannabis reform at USCC. MPP will remain a member of USCC and continue to share staff, board members and resources.  “Toi’s unique resume is perfectly suited to lead MPP as we finish our reform work state-by-state across the country,” MPP Board Chairman Sal Pace said. “Toi worked alongside MPP as one of the initial authors of the Illinois adult-use cannabis legislation to ensure that the law contained a strong social justice framework that included decriminalization in addition to legalization. MPP has always been focused not only on legalization but also on doing it right and ending the war on drugs.” “I am proud of what we have accomplished at MPP and look forward to working alongside Toi in the fight to end cannabis prohibition,” said Hawkins, president and CEO of USCC. “MPP played a pivotal role in incubating USCC, and we are now taking that work to the next level. Toi is an incredible leader, and I know that our organizations will work tirelessly to advance our shared goals.” “The MPP Board is thrilled with the work Steve accomplished during his four-year tenure. These past four years have been the most productive years yet for marijuana reform. MPP will continue to work with Steve as a member organization of USCC, including continuing to share some staff between the two organizations,” Pace said. “I’m pleased to be joining the team at MPP, where I will continue my years-long effort to develop and support cannabis legalization legislation that centers on equity and repairing the harms of the past,” Hutchinson said. “We are incredibly proud of the hard work and lessons learned in Illinois, standing up programs to invest in equity entrepreneurs, reinvesting in communities, and clearing hundreds of thousands of arrests and criminal records.  “Steve Hawkins’ work at MPP was stellar, and I look forward to working with him in his new capacity along with legislators and partners across the country to advance the goals and mission of MPP by harnessing our collective power to advocate for changes to federal cannabis policies.” In addition to her position as senior adviser to Pritzker, Hutchinson also served as an Illinois state senator and an attorney at the law firm of Chapman and Cutler. She earned a bachelor’s degree in Liberal Arts and Sciences (English) from the University of Illinois and a Juris Doctor from Northern Illinois University College of Law.  Hutchinson is a member of the Chicago Federation of Women, the Illinois Women’s Institute for Leadership, Links, International, and Alpha Kappa Alpha Sorority, Inc.      Since MPP was founded in 1995, it has spearheaded most of the major state-level reforms that have occurred over the past two decades. MPP played a leading role in 10 of the 18 adult-use legalization laws, starting with the historic 2012 Amendment 64 initiative in Colorado, which was the first state to legalize cannabis for adults. MPP also led the coalitions that passed initiatives to legalize and regulate cannabis in Alaska, Maine, Massachusetts, Nevada, Michigan and Montana between 2014 and 2021.  MARSHALL, Mich., Dec. 20, 2021 – PRESS RELEASE – Common Citizen, which produces safe, high-quality cannabis products for patients and adult-use customers, announced the launch of its Principle product line, which is now available at its retail stores. All net proceeds from Principle sales go back into the communities Common Citizen proudly serves. Principle cannabis is now available in a single, 1-gram pre-roll in a decorative tin at Common Citizen’s retail locations. “Our Principle product line embodies our priority of people over product, and arrives just in time for the holidays to help our ongoing efforts to reinvest in the diverse communities we proudly call home,” Common Citizen CEO Michael Elias said. “The Principle project also helps us educate the common citizen about the many wellness benefits of cannabis and helps achieve our goal of eliminating stigma around its production, distribution and consumption.” Principle was unveiled at a recent two-day media event, which included a tour of Common Citizen’s state-of-the-art hybrid greenhouse in Marshall and the company’s flagship retail location in Flint. The event included dignitaries and members of the national media and culminated in the launch of the film “Cannabis For Humanity” in Detroit. The film embodies Common Citizen’s mission to serve the unique cannabis needs of patients and adult-use customers across Michigan. A public release date for the film will soon be announced. Watch a preview of the film here. Creating tangible impact through cannabis ventures requires action, sustained engagement and collaboration with partners already doing transformative work to achieve this goal. To help advance these efforts, Common Citizen has partnered with Cannaclusive to better serve its employees and local communities. In the coming months, Cannaclusive will help Common Citizen direct its profits to organizations dedicated to creating meaningful opportunities for marginalized communities. As company advisers, Cannaclusive will also support Common Citizen’s ongoing initiatives to develop and scale internal programs that facilitate diversity, equity and inclusion. “Principle is the next step in our mission of serving Cannabis For Humanity and the individual needs of our patients and adult-use customers,” Elias said. “I encourage all our customers to add Principle to their holiday shopping list and help us give back to our communities during this special time of year.”
垂直整合的多州大麻(和CBD)运营商库拉雷夫控股公司(Curaleaf Holdings)可能面临非法死亡诉讼,这是一系列与标签错误产品有关的诉讼中的最新一起。 根据俄勒冈州白酒和大麻委员会(OLCC)发布的一份产品召回通知,Curaleaf目前面临10起消费者诉讼,据称他们摄入了一种标签错误的CBD酊剂,其中含有“未披露的四氢大麻酚水平”。 召回于9月21日发布,针对一批标签错误的CBD产品,该产品由Cura CS LLC生产,以Curaleaf的精选品牌销售。2019年,Curaleaf以9.488亿美元的全股票交易收购了Cura及其精选品牌。 Curaleaf首席法律官彼得·克莱特曼(Peter Clateman)告诉《大麻商业时报》和大麻种植者,这批产品售出了约500瓶。 OLCC在9月24日扩大了召回范围,包括另一种精选酊剂,该酊剂在标签上表示含有1000毫克四氢大麻酚,但在一轮初步测试后,OLCC发现该产品不含任何可检测到的四氢大麻酚。根据OLCC的数据,Curaleaf估计售出了630单位标签错误的酊剂。 Curaleaf承认这两种酊剂的标签错误是由“人为错误”造成的。 “所以,发生的最基本的事情是,有一名员工将两套成分混合在一起,并将含四氢大麻酚的成分放入CBD产品中。这是一个错误,这是一个明显的错误,仅仅因为产品被贴上了标签,员工感到困惑。克莱特曼说:”他没有升级或寻求解决困惑,而是继续填充产品。““我们已经做了根本原因分析,这就是我们要做的。这名员工已经被重新分配到生产工作岗位。” 标签错误的产品现已导致多人对该公司提起诉讼,其中大多数由俄勒冈州波特兰市失败者律师事务所的合伙人迈克尔·富勒代理。 富勒说,“数十人”联系了该公司,对标签错误的产品表示类似的担忧。 富勒说:“他们中的大多数人是通过记者的介绍联系我的。一名爱达荷州男子住院后第一个联系(律师事务所)讲述他的经历。” 富勒说,将原告介绍给律师事务所的记者从富勒去年对库拉提出的集体诉讼中认出了该事务所。据《波特兰商业日报》报道,标签错误的产品未能说明它们含有非大麻衍生的植物萜烯,Cura表示,这一错误是无意的,是由于“其制造、标签和包装人员之间的沟通不畅”。(据PBJ报道,库拉还因标签错误事故面临OLCC 11万美元的罚款。)富勒说:“我们通过谈判达成了50万美元的索赔解决方案。” “这不应该仅仅因为这是一个相对较新的行业就发生。富勒说:”这根本没有借口,他们正在阻止(合法化)运动。“不是意外,是偷工减料。” 诉讼分项 在最近的诉讼中,富勒说,他的所有客户--从30多岁的男性和女性到70多岁的个人--都声称,他们在据称消费了标签错误的CBD产品后,出现了“中风样”症状。富勒说,一些所谓的症状包括口齿不清、浪费时间、无法站立、幻觉、精神病、恐慌、重击、心率和认为自己会死。 他说,他的大约六名客户在消费后去了急诊室--其中一人据称生命垂危--在消费后的两个不同场合,另一人据称因误诊中风而接受了“不必要的手术”。 他补充说,他的许多客户声称他们多次消费该产品,但没有意识到其中含有四氢大麻酚。 这起非法死亡诉讼称,据报道,两次生命飞逝的原告在消费后第二次去医院几周后死于新冠肺炎;然而,富勒说,他的家人认为“THC剂量是他无法在COVID中生存的一个重要因素”。 “他的家人认为不是THC杀死了他,但他的家人认为,这是影响他健康的一个重要因素,基本上,在那次经历后,……确信他会死;富勒说:”他们说他再也不一样了。“并补充说,据称这一经历”削弱了他。“ 富勒说,他的案件目前正在等待遗嘱认证,一旦法院批准文件,将提起非法死亡诉讼。 “我们只是在等待法官的签名,”富勒说。“这是俄勒冈州一个非常小的县,叫做莱克县。因此,我们对那里处理事情的速度没有很大的控制权,但我们已经起草了诉讼,我们只需要莱克县法官任命个人代表的判决,因为这是一项遗产索赔,然后将提交投诉。“ 富勒说,所有这些索赔都是相当“简单”的产品责任案件,因为他认为Curaleaf并没有否认它“在广告中只含有CBD的瓶子里添加四氢大麻酚违反了法律”。 12月16日,Curaleaf的通信部门通过电子邮件向《大麻商业时报》/大麻种植者做出了以下回应: Curaleaf声明:THC/CBD产品标签错误 虽然我们不能对任何悬而未决的诉讼发表评论,但我们可以做出以下回应: 一名队员在灌装包装过程中混淆了两个集装箱,一个装CBD,一个装THC。这导致单批[CBD]酊剂被标记为四氢大麻酚[滴剂],反之亦然。四氢大麻酚的量在我们的四氢大麻酚滴剂的正常批次的监管限制范围内,但我们理解一些客户可能已经消费了多个剂量。 我们已经与OLCC合作召回了两批有问题的产品,剩下的有限数量的产品已经停止销售。 作为对此事件的回应,作为第一步,[我们]调整了生产实践并实施了新的控制措施,以改进质量保证过程,进一步将人为错误的可能性降至最低,提高了产品控制区域的摄像机可见性,并与我们的生产团队进行了额外的培训。我们还将增加对部门间产品转移、批量记录和其他文件的二次审查。 我们还增加了一个新的质量技术员职位[我们的俄勒冈州工厂],并已删除了在灌装和包装过程中对错误负责的个人。我们将继续与当地的运营团队密切合作,以确保在生产的每一步都遵循安全和合规的最佳实践。 下一步 有些案件已经解决了。 克莱特曼说:“我们的方法是友好地处理,并试图与经历过该产品负面影响的人达成和解。” 活跃的案件将分别向前推进,富勒说,他预计其中一些案件将在明年中至晚些时候得到解决,其他案件将进行审判。 华盛顿,2021年12月15日--新闻稿--大麻政策项目宣布,托伊·哈钦森将加入该组织,担任其新总裁兼首席执行官。哈钦森是前伊利诺伊州参议员,最近担任伊利诺伊州州长J.B.的高级顾问普利兹克谈大麻合法化的实施。 在过去的一年里,MPP执行主任史蒂文·霍金斯领导了MPP和美国大麻理事会(USCC)。霍金斯现在将专注于USCC的联邦大麻改革。MPP将继续作为USCC的成员,并继续共享员工、董事会成员和资源。 MPP董事会主席萨尔·佩斯(Sal Pace)表示:“随着我们在全国逐州完成改革工作,托伊独特的简历非常适合领导MPP。”“TOI作为伊利诺伊州成人使用大麻立法的最初作者之一,与MPP合作,以确保该法律包含一个强有力的社会正义框架,除了合法化之外,还包括非刑罪化。MPP一直不仅专注于合法化,而且致力于做好这件事,结束禁毒战争。“ USCC总裁兼首席执行官霍金斯说:“我为我们在MPP取得的成就感到骄傲,并期待着与Toi一起努力结束大麻禁令。”“MPP在孵化USCC方面发挥了关键作用,我们现在正在将这项工作推向下一个水平。Toi是一位不可思议的领导者,我知道我们的组织将不知疲倦地努力推进我们的共同目标。“ “MPP董事会对史蒂夫在四年任期内完成的工作感到兴奋。过去的四年是大麻改革最富有成效的几年。MPP将继续作为USCC的成员组织与史蒂夫合作,包括继续在两个组织之间共享一些员工,“佩斯说。 哈钦森说:“我很高兴加入MPP的团队,在那里我将继续我多年的努力,发展和支持大麻合法化立法,该立法以公平和修复过去的伤害为中心。”“我们为伊利诺伊州的辛勤工作和吸取的教训感到无比自豪,我们支持投资股本企业家的项目,对社区进行再投资,并清除了数十万人的逮捕和犯罪记录。 “史蒂夫·霍金斯在MPP的工作非常出色,我期待着以他的新身份与全国各地的立法者和合作伙伴合作,通过利用我们的集体力量倡导改变联邦大麻政策,推进MPP的目标和使命。” 除了担任普利兹克的高级顾问之外,哈钦森还担任伊利诺伊州参议员和查普曼和卡特勒律师事务所的律师。她在伊利诺伊大学获得文理学士学位(英语),并在北伊利诺伊大学法学院获得法学博士。 哈钦森是芝加哥妇女联合会、伊利诺伊州妇女领导力研究所、链接、国际和阿尔法·卡帕·阿尔法联谊会的成员。 自1995年成立以来,它领导了过去20年来发生的大多数重大国家一级改革。MPP在18项成人使用合法化法律中的10项中发挥了主导作用,从科罗拉多州历史性的2012年第64修正案倡议开始,科罗拉多州是第一个将成人大麻合法化的州。MPP还领导了2014年至2021年间在阿拉斯加、缅因州、马萨诸塞州、内华达州、密歇根州和蒙大拿州通过大麻合法化和监管倡议的联盟。 马歇尔, 密歇根州,2021年12月20日--新闻稿--为患者生产安全、高质量大麻产品的普通公民 成人使用的客户,宣布推出其主要产品线,这是现在 在其零售店可买到。原则销售的全部净收益退回 为社区普通公民自豪地服务。 原则 大麻现在可以在一个装饰性的罐头里买到一个1克的预卷 普通市民的零售点。 “我们的 原则产品线体现了我们的人优先于产品,以及 正好赶上假期,帮助我们继续努力进行再投资 在我们自豪地称之为家的不同社区,“共同公民首席执行官迈克尔·埃利亚斯 说。“原则项目还帮助我们教育普通公民 大麻的许多健康益处,并有助于实现我们消除 围绕其生产、销售和消费的污名。“ 原则 在最近的一次为期两天的媒体活动中亮相,其中包括一次公共旅行 位于马歇尔的Citizen最先进的杂交温室和该公司的 弗林特的旗舰零售点。这次活动包括政要和成员 并最终在底特律推出了电影《大麻造福人类》。 这部电影体现了普通公民服务于独特大麻需求的使命 密歇根州的病人和成人用户。公开发布日期 这部电影很快就要宣布了。 手表 这里有电影的预览。 创作 通过大麻冒险活动产生切实影响需要采取行动、持续参与 并与已经在进行变革性工作的伙伴合作,以实现 这个目标。为了帮助推进这些努力,共同公民与 更好地为员工和当地社区服务。在未来 几个月来,甘露将帮助普通公民将其利润直接用于 致力于为边缘化群体创造有意义机会的组织 社区。 作为 公司顾问,Cannaclusive也将支持普通公民正在进行的 制定和扩大促进多样性的内部方案的倡议, 公平和包容。 “原则 是我们为人类和 我们的病人和成人用户的个人需求,“埃利亚斯说。“我 鼓励我们所有的顾客在他们的假日购物清单上增加原则和 在一年中的这个特殊时刻,帮助我们回馈我们的社区。“

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文